Face‐to‐face: isotretinoin use and pregnancy outcome
International Journal of Dermatology · 2024
DOI: 10.1111/ijd.16953 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Zeynep Tırmıkçıoğlu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology Unit, Izmir Ataturk Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Isotretinoin, Abnormalities, Drug-Induced. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Isotretinoin has been used to treat severe acne for more than 40 years. There are no accurate data on the absolute risk of potential teratogenicity to all fetuses exposed to isotretinoin. According to current guidelines, isotretinoin should be discontinued at least 1 month before pregnancy. This study enrolled pregnant women who contacted the Clinical Pharmacology and Toxicology Unit for individual drug risk assessment between 2016 and 2020. Data on maternal characteristics and isotretinoin exposures were obtained at first consultation. After delivery, follow‐up calls were conducted using a structured questionnaire. Of 2,323 pregnant women consulted, 1.3% (31/2,323) had systemic isotretinoin exposure during and before pregnancy. Of 31 prospectively followed pregnancies, eight terminated electively. Most elective terminations (7/8) were performed because of the fear of fetal malformation. The majority of continued pregnancies (16/23) resulted in healthy live birth. There were no major birth defects. In six pregnancies, intrauterine deaths (three first trimester, three second trimester) were reported. Cesarean section was performed in 70.5% (12/17) of all deliveries. The median gestational age at birth was 39, and no preterm births were reported. Local isotretinoin treatments in six cases were evaluated and presented additionally, and all babies were born healthy. Based on the results of this study, there was no evidence of major birth defect, mental disorder, or retinoid embryopathy associated with the use of isotretinoin in pregnancy. Not local use, but systemic exposure to isotretinoin is of great concern that results in pregnancy termination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Toxicology Unit, Izmir Ataturk Research Hospital, Izmir, Turkey.
- Department of Dermatology, Faculty of Medicine, Usküdar University, Istanbul, Turkey.
ORCID-Profile: Zeynep Tırmıkçıoğlu
Zitieren
APA
Tırmıkçıoğlu, Z., & Tatlıparmak, A. (2024). Face‐to‐face: isotretinoin use and pregnancy outcome. International Journal of Dermatology. https://doi.org/10.1111/ijd.16953
Vancouver
Tırmıkçıoğlu Z, Tatlıparmak A. Face‐to‐face: isotretinoin use and pregnancy outcome. International Journal of Dermatology. 2024. doi:10.1111/ijd.16953
BibTeX
@article{Trmkolu2024,
author = {Tırmıkçıoğlu, Zeynep and Tatlıparmak, Aslı},
title = {Face‐to‐face: isotretinoin use and pregnancy outcome},
journal = {International Journal of Dermatology},
year = {2024},
doi = {10.1111/ijd.16953}
}
EUVIMED